New combo tackles tough breast cancer brain metastases
NCT ID NCT03483012
First seen Jan 02, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This study tested a combination of the immunotherapy drug atezolizumab and precise radiation (stereotactic radiosurgery) in 6 people with triple-negative breast cancer that had spread to the brain. The goal was to see if the combo could slow or stop the cancer from growing. The trial is now complete, but results are not yet widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq) and stereotactic radiosurgery
What this could lead to
If successful, this combination could offer a new way to control triple-negative breast cancer that has spread to the brain, potentially improving survival.
What could go wrong
This is a very small, early-phase study (only 6 participants), so results may not apply to larger groups. The treatment may not work better than standard care and could cause side effects from both the drug and radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.